Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:KALANASDAQ:KURANASDAQ:MTEMNASDAQ:NXTC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.91+4.6%$0.74$0.50▼$5.20$49.74M0.7736,299 shs637,269 shsKALAKALA BIO$7.84-0.1%$7.35$5.10▼$19.57$21.09M-1.8629,403 shs9,908 shsKURAKura Oncology$21.33+0.8%$20.50$7.41▼$24.17$1.62B0.861.48 million shs867,488 shsMTEMMolecular Templates$2.24-5.1%$3.32$1.68▼$9.45$12.03M1.221,885 shs377,259 shsNXTCNextCure$2.23+14.9%$1.50$0.98▼$2.28$62.22M0.37254,669 shs1.02 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics+4.72%+2.06%-3.75%+22.48%-82.09%KALAKALA BIO-0.13%-0.25%+9.65%+12.00%-47.10%KURAKura Oncology+0.76%-0.09%-1.98%+48.33%+73.27%MTEMMolecular Templates-4.68%+24.44%-44.42%-39.95%-55.37%NXTCNextCure+15.25%+32.74%+42.49%+95.61%+45.75%Grab Your Free Bitcoin Today! (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics4.5279 of 5 stars3.42.00.04.24.41.71.3KALAKALA BIO4.4165 of 5 stars3.53.00.04.42.11.71.3KURAKura Oncology4.161 of 5 stars3.43.00.04.73.80.80.0MTEMMolecular Templates3.2588 of 5 stars0.05.00.04.63.92.50.6NXTCNextCure4.5507 of 5 stars3.53.00.04.42.91.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.75971.43% UpsideKALAKALA BIO3.00Buy$22.00180.61% UpsideKURAKura Oncology2.88Moderate Buy$28.2832.57% UpsideMTEMMolecular TemplatesN/AN/AN/AN/ANXTCNextCure3.00Buy$6.00169.06% UpsideCurrent Analyst RatingsLatest CARA, KURA, NXTC, KALA, and MTEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/6/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/28/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.002/28/2024KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$37.001/31/2024KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $32.001/22/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M2.37N/AN/A$1.05 per share0.87KALAKALA BIO$3.89M5.42N/AN/A$11.12 per share0.71KURAKura OncologyN/AN/AN/AN/A$5.35 per shareN/AMTEMMolecular Templates$19.75M0.61N/AN/A($4.03) per share-0.56NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)KALAKALA BIO-$44.82M-$22.73N/AN/AN/AN/A-259.42%-64.39%3/29/2024 (Estimated)KURAKura Oncology-$152.63M-$2.08N/AN/AN/AN/A-36.30%-33.12%5/8/2024 (Estimated)MTEMMolecular Templates-$92.72M-$6.67N/AN/AN/A-49.57%N/A-43.85%4/4/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)Latest CARA, KURA, NXTC, KALA, and MTEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/27/2024Q4 2023KURAKura Oncology-$0.56-$0.55+$0.01-$0.55N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43KALAKALA BIO3.365.625.62KURAKura Oncology0.0212.2612.26MTEMMolecular TemplatesN/A1.061.06NXTCNextCureN/A16.3816.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%KALAKALA BIO24.61%KURAKura OncologyN/AMTEMMolecular Templates95.47%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%KALAKALA BIO13.40%KURAKura Oncology5.40%MTEMMolecular Templates18.70%NXTCNextCure11.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableKALAKALA BIO342.69 million2.33 millionNot OptionableKURAKura Oncology14276.14 million72.03 millionOptionableMTEMMolecular Templates1115.37 million4.37 millionNo DataNXTCNextCure8227.90 million24.58 millionOptionableCARA, KURA, NXTC, KALA, and MTEM HeadlinesSourceHeadlineNextCure, Inc. (NASDAQ:NXTC) Short Interest Updatemarketbeat.com - March 27 at 10:15 PMWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?finance.yahoo.com - March 27 at 10:07 AMWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Richinvestorplace.com - March 23 at 6:00 AMNextCure (NASDAQ:NXTC) Given New $8.00 Price Target at HC Wainwrightamericanbankingnews.com - March 23 at 5:42 AMPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy Ratingmarkets.businessinsider.com - March 22 at 5:19 PMHC Wainwright Boosts NextCure (NASDAQ:NXTC) Price Target to $8.00marketbeat.com - March 22 at 2:58 PMNextCure (NASDAQ:NXTC) Rating Reiterated by Needham & Company LLCamericanbankingnews.com - March 22 at 2:56 AMAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)markets.businessinsider.com - March 21 at 9:15 PMNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug Candidatesmarketwatch.com - March 21 at 4:06 PMNextCure to lay off 37% of staff, dial back research plansbiopharmadive.com - March 21 at 4:06 PMMd. biopharma lays off staff, pauses manufacturing to preserve cashbizjournals.com - March 21 at 4:06 PMNextCure Provides Business Update and Reports Full Year 2023 Financial Resultsglobenewswire.com - March 21 at 8:55 AMNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advancesglobenewswire.com - March 5 at 8:05 AMNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disordersfinance.yahoo.com - January 18 at 6:56 PMNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and Datesbenzinga.com - December 28 at 3:49 PMHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishingfinance.yahoo.com - December 25 at 2:02 PMNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injuryfinance.yahoo.com - December 21 at 7:59 AMNextCure (NXTC) Down on Shelving Plans to Develop Candidatefinance.yahoo.com - December 15 at 1:35 PMBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline Shiftmarkets.businessinsider.com - December 15 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)markets.businessinsider.com - December 15 at 12:33 AMNextCure stock falls 20% amid program shutdown, business updatemsn.com - December 14 at 7:32 PMNextCure Shares Fall 26% After Halting Development of One Drug Candidatemarketwatch.com - December 14 at 9:31 AMNextCure Provides Year-End Clinical Pipeline Updatesfinance.yahoo.com - December 14 at 9:31 AMNextCure to Present at the 35th Annual Piper Sandler Healthcare Conferencefinance.yahoo.com - November 20 at 8:25 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Kura OncologyNASDAQ:KURAKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Molecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.